KC Lim JG Song DK. Protection of pancreatic beta-cells against glucotoxicity by short-term treatment with GLP-1 . Biochemical and Biophysical Research Communications 2015 459 561 – 567 . ( doi:10.1016/j.bbrc.2015.02.139 ) 21
Search Results
Xuhua Mao, Hucheng Chen, Junmin Tang, Liangliang Wang, and Tingting Shu
Angelica Amorim Amato, Hailey Brit Wheeler, and Bruce Blumberg
additional mechanisms that may mediate its obesogen effect. Such actions include impairment of glucagon-like peptide-1 (GLP-1) secretion, an important hormone regulating appetite, by the enteroendocrine cell line STC-1, ( 125 ) and/or androgen receptor action
Helle Keinicke, Gao Sun, Caroline M Junker Mentzel, Merete Fredholm, Linu Mary John, Birgitte Andersen, Kirsten Raun, and Marina Kjaergaard
recognized as metabolic regulatory molecules. Stimulation of the BA receptor TGR5 increases EE in BAT as well as GLP-1 secretion in the intestinal L-cells ( 53 ). Also, in gastric bypass patients, increased BA has been suggested to contribute to the improved
Raluca Maria Furnica, Muhammad Muddaththir Dusoruth, Alexandre Persu, Damien Gruson, Michel Mourad, and Dominique Maiter
Petrák O Klímová J Mráz M Haluzíková D Doležalová RP Kratochvílová H Lacinová Z Novák K Michalsky D Waldauf P Pheochromocytoma with adrenergic biochemical phenotype shows decreased GLP-1 secretion and impaired glucose tolerance
Lei Lei, Yi-Hua Bai, Hong-Ying Jiang, Ting He, Meng Li, and Jia-Ping Wang
-cell-specific genes, such as insulin, Glut2, Pdx-1, Nkx6.1, GLP-1R, PC-1/3, and pyruvate carboxylase ( 36 ). Studies have shown that MAFA is an important regulator of glucose-stimulated insulin secretion ( 37 ), and it can drive insulin expression by binding to the
Aldo Bonaventura, Fabrizio Montecucco, and Franco Dallegri
.1517/14740338.2012.694424 ). 78 Aroda VR Henry RR Han J Huang W DeYoung MB Darsow T Hoogwerf BJ . Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review . Clinical Therapeutics 2012 34 1247 – 1258 . ( doi:10.1016/j
Xiaolei Hu and Fengling Chen
capacity of IAs and insulin; metformin may strengthen the action of free insulin and promote the dissociation of insulin immune complexes; and GLP-1 receptor agonists, as potent stimulators of insulin secretion, especially in combination with sulfonylurea
Chunliang Yang, Junyi Li, Fei Sun, Haifeng Zhou, Jia Yang, and Chao Yang
, 2 ). Existing therapeutics are aimed at lowering blood glucose level by stimulating insulin secretion (direct: sulfonylureas, nateglinide; indirect: DPP-4 inhibitors/GLP-1), alleviating peripheral insulin resistance (Metformin, TZDs), reducing
Irvin M Modlin, Harry Aslanian, Lisa Bodei, Ignat Drozdov, and Mark Kidd
cell tumors), as well as small intestinal ‘carcinoids’ (secretin, serotonin, and a variety of tachykinins) and colorectal lesions (enteroglucagon, GLP1, and pancreatic polypeptide (PP)). The conundrum of identifying a global marker for NETs therefore
Frederique Van de Velde, Marlies Bekaert, Anja Geerts, Anne Hoorens, Arsène-Hélène Batens, Samyah Shadid, Margriet Ouwens, Yves Van Nieuwenhove, and Bruno Lapauw
- or hyperthyroidism or a recent change in their medication. In total 16 subjects were excluded from the analysis; due to use of GLP-1 analogue ( n = 1) or insulin ( n = 7), refusing liver biopsy ( n = 1), no scored liver biopsy ( n = 4), no blood
